Gene · 6607
NIH grants1,484
NIH grants whose papers are about the gene, through NIH's grant-paper links.
821 to 840 of 1,484
Download this page as JSON| Grant | Title | SMN2 papers | Newest fiscal year |
|---|---|---|---|
| R01HL126729 | Targeting Nav1.5 trafficking as a therapy for lethal genetic cardiac arrhythmias | 1 | 2018 |
| R01MH102342 | Integrating the genomics of Autism Spectrum Disorders(ASD) in consanguineous and "idiopathic" families | 1 | 2018 |
| R01MH103220 | Neurophysiological markers of HAND and the impact of aging: Evidence from MEG | 1 | 2018 |
| R01MH104147 | Novel Kinase and Nanoformulated Protease Inhibitors for Eradication of CNS HIV-1 | 1 | 2018 |
| R01MH107354 | Integration of fMRI imaging, genomics, network and biological knowledge | 1 | 2018 |
| R01MH109901 | 1/3 Multidimensional investigation of the etiology of autism spectrum disorder | 1 | 2018 |
| R01MH109904 | 3/3 Multidimensional investigation of the etiology of autism spectrum disorder | 1 | 2018 |
| R01NS062856 | Mechanisms of Gene Silencing of Friedreich's Ataxia | 1 | 2018 |
| R01NS087227 | Using RNA signatures for therapy development in neurodegeneration due to C9orf72 expansions | 1 | 2018 |
| R01NS097816 | Understanding SOD1 Kinetics in Amyotrophic Lateral Sclerosis | 1 | 2018 |
| R15DK114740 | Liver-Adipose tissue crosstalk in NAFLD: Role of the Novel Adipokine CTRP3 | 1 | 2018 |
| R21DE025920 | Comprehensive Identification of FXR1 Targets Using pSILAC-BONCAT Proteomics | 1 | 2018 |
| R21NS098186 | Changing serotonin receptor 2C splice variants to combat spasticity after spinal cord injury | 1 | 2018 |
| R21NS098363 | The Role of p38 MAPK Activation in Spinal Muscular Atrophy | 1 | 2018 |
| R21NS101395 | Functional long noncoding RNAs in human glioma | 1 | 2018 |
| R21NS102687 | Isolating small-molecule enhancers of HtrA1, an alpha-synuclein disaggregase | 1 | 2018 |
| R21OD023824 | A light-inducible protein trapping system for studying cellular dynamics in Drosophila | 1 | 2018 |
| R41AG060836 | Small Molecule Inhibitor Therapeutic Target for Alzheimer's Disease. | 1 | 2018 |
| R56AI138613 | Chemical, Nanomedicine and Autophagy Strategies to Create Sustained-Release Antiretroviral Products | 1 | 2018 |
| RF1AG015473 | Genetic Studies of Alzheimer's Disease in Caribbean Hispanics | 1 | 2018 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6607/grants?page=42